Amphetamine News and Research

RSS

Dramatic rise in substance abuse treatment admission rates from 1999-2009

A new report shows that while the overall rate of substance abuse treatment admissions among those aged 12 and older in the United States has remained nearly the same from 1999 to 2009, there has been a dramatic rise (430 percent) in the rate of treatment admissions for the abuse of prescription pain relievers during this period.

9 Dec 2011

Drug abuse high in West Australian young men: Study

According to a drug expert almost one in 10 men under 30 years of age has regularly used stimulant drugs and West Australians are the worst offenders.

21 Nov 2011

Intelligent children more likely to abuse drugs as teens and adults: Study

A new study finds that children with high IQs are more likely to use marijuana, cocaine, amphetamines and other illicit drugs as teenagers and adults. This comes after an in-depth look at nearly 8,000 British men and women who were tracked for more than three decades.

16 Nov 2011

Link between heavy methamphetamine use and schizophrenia

In the first worldwide study of its kind, scientists from Toronto's Centre for Addiction and Mental Health (CAMH) found evidence that heavy methamphetamine users might have a higher risk of developing schizophrenia.

8 Nov 2011

Amphetamine use in adolescence can affect brain chemistry and behaviour

Amphetamine use in adolescence can cause neurobiological imbalances and increase risk-taking behaviour, and these effects can persist into adulthood, even when subjects are drug free. These are the conclusions of a new study using animal models conducted by McGill University Health Centre (MUHC) researcher Dr. Gabriella Gobbi and her colleagues.

4 Nov 2011

IRMS tracks course of designer 'legal high' drugs manufacture

Urgently needed tests which could help identify the manufacturers of designer 'legal high' drugs are being developed in research led at the University of Strathclyde in Glasgow.

14 Oct 2011

Caffeine may predict risk of drug abuse

Parents of young caffeine consumers take heed: that high-calorie energy drink or soda might present more than just obesity risk. In fact, according to a double-blind, placebo-controlled study that examined responses to stimulants, an individual's subjective response to caffeine may predict how he or she will respond to other stimulant drugs, possibly reflecting differences in risk for abuse of other more serious drugs of abuse, such as amphetamine and cocaine.

10 Oct 2011

UN report on illicit drug use worldwide

According to a new United Nations report the use of stimulant drugs of abuse like amphetamine, ecstasy and meth is increasing worldwide. The report adds that the growing trade in these illegal drugs and the high profits they bring to criminals are posing an increasing threat to health and security.

14 Sep 2011

Western, Midwestern states register higher methamphetamine usage

Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, today issued its annual report on U.S. worker drug use, the Quest Diagnostics Drug Testing Index.

From Quest Diagnostics 2 Sep 2011

Curemark's novel compound CM-182 shows promise for treatment of hyperactivity without sedation

Curemark, LLC, a drug research and development company focused on the treatment of neurological diseases, announced today that its compound CM-182 demonstrated positive results for reduction in hyperactivity in mice treated with amphetamines. The mouse model screening was performed by the contract research organization, Cerca Insights.

29 Aug 2011

Lightlake to begin opioid antagonist derived nasal spray Phase II trials in Binge Eating Disorder

Lightlake Therapeutics Inc., an early stage biopharmaceutical company currently developing a nasal spray for the treatment of overweight and obese patients with Binge Eating Disorder, today announced that its patient testing stage of the Phase II clinical trials will start August 26th, 2011

25 Aug 2011

Scientists identify new therapeutic target for ADHD, other neuropsychiatric disorders

A biochemical pathway long associated with diarrhea and intestinal function may provide a new therapeutic target for treating ADHD other neuropsychiatric disorders, according to a team of scientists from China and the United States reporting Aug. 11 in Science.

12 Aug 2011

Research: p38α MAPK protein plays a role in addiction, depression-like behavior

Researchers studying mice are getting closer to understanding how stress affects mood and motivation for drugs.

11 Aug 2011

Amphetamines can control ADHD symptoms in adults

Giving amphetamines to adults with Attention Deficit Hyperactivity Disorder (ADHD) can help them control their symptoms, but the side effects mean that some people do not manage to take them for very long.

27 Jul 2011

Methamphetamine users more likely to develop Parkinson's disease

People who abused methamphetamine or other amphetamine-like stimulants were more likely to develop Parkinson's disease than those who did not, in a new study from the Centre for Addiction and Mental Health.

27 Jul 2011

Quitting cannabis use in your 20s cuts progression to other drugs

Quitting cannabis use in your 20s significantly reduces your chance of progressing to other illicit drug use, according to research published online in the Journal of Epidemiology and Community Health.

18 Jul 2011

Platelet-derived growth factor-BB restores function in rats with Parkinson's disease

Few treatments for Parkinson's disease (PD) restore function for extended periods. In a new study published today in the inaugural issue of the Journal of Parkinson's Disease, an international group of researchers report that platelet-derived growth factor-BB (PDGF-BB) restored function in rodents and shows promise as a clinical candidate drug for treatment of PD.

10 Jun 2011

Study shows why individuals with anorexia nervosa have paradoxical response to food

Perhaps the most puzzling symptom of anorexia nervosa - a disorder that tends to occur in young women - is the refusal to eat, resulting in extreme weight loss. While most people have a great deal of difficulty in dieting and losing weight, particularly if a diet extends over many months or years, individuals with anorexia nervosa can literally diet themselves to death. In fact, this disorder has a very high death rate from starvation.

21 May 2011

Positive results from Shire's Vyvanse clinical trial in schizophrenia

Shire plc, the global specialty biopharmaceutical company, today announced positive results from a signal-finding study of Vyvanse(R) Capsules assessing its effect in a prospective examination of adults with negative symptom predominant schizophrenia.

28 Apr 2011

KemPharm to formulate and develop KP106 as oral film dosage for ADHD treatment

KemPharm, Inc. today announced that KP106, its clinical candidate for Attention Deficit/Hyperactivity Disorder, will be formulated and developed in an oral film dosage form pursuant to an exclusive collaboration agreement with MonoSol Rx relating to the development, commercialization and manufacture of KP106.

26 Apr 2011